Holen Sie sich die Stockscreener-App
29.66
1.49%
-0.295
Handel nachbörslich:
29.67
0.005
+0.02%
Schlusskurs vom Vortag:
$29.96
Offen:
$29.98
24-Stunden-Volumen:
4.13M
Relative Volume:
0.73
Marktkapitalisierung:
$21.34B
Einnahmen:
$8.26M
Nettoeinkommen (Verlust:
$-397.91M
KGV:
-58.91
EPS:
-0.5036
Netto-Cashflow:
$-758.56M
1W Leistung:
+4.62%
1M Leistung:
+7.68%
6M Leistung:
+41.42%
1J Leistung:
+171.52%
1-Tages-Spanne:
$29.31
$30.35
1-Wochen-Bereich:
$29.31
$32.79
52-Wochen-Spanne:
$10.59
$32.79
Roivant Sciences Ltd Stock (ROIV) Company Profile
Firmenname
Roivant Sciences Ltd
Sektor
Branche
Telefon
441-295-5950
Adresse
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
29.66 | 21.55B | 8.26M | -397.91M | -758.56M | -0.5036 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-20 | Eingeleitet | Bernstein | Outperform |
| 2025-09-02 | Eingeleitet | Citigroup | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-01-05 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-17 | Eingeleitet | Guggenheim | Buy |
| 2023-06-08 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-27 | Eingeleitet | JP Morgan | Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-12-15 | Eingeleitet | Goldman | Buy |
| 2021-11-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-28 | Eingeleitet | Citigroup | Buy |
| 2021-10-26 | Eingeleitet | Cowen | Outperform |
| 2021-10-26 | Eingeleitet | Jefferies | Buy |
| 2021-10-26 | Eingeleitet | Truist | Buy |
Alle ansehen
Roivant Sciences Ltd Aktie (ROIV) Neueste Nachrichten
Roivant Sciences Insider Sold Shares Worth $6,054,000, According to a Recent SEC Filing - Moomoo
Technical Reactions to ROIV Trends in Macro Strategies - Stock Traders Daily
Assessing Roivant Sciences (ROIV) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
Roivant Shelf Plan Raises Questions On Dilution And Pipeline Funding - simplywall.st
TD Cowen Raises its Price Target on Roivant Sciences (ROIV) - Insider Monkey
Litigation Windfall Driving Roivant Sciences’ Profit Swing Might Change The Case For Investing In Roivant Sciences (ROIV) - Yahoo Finance
Today's Analyst Rating | Roivant Sciences Price Target Raised to $31.5 by BofA Securities, UBS Downgrades Millicom International Cellular to Hold - Moomoo
Roivant Sciences Ltd. (ROIV) - DirectorsTalk Interviews
Roivant gains after mid-stage trial data for Immunovant’s main asset - MSN
Roivant shares climb on earnings beat despite revenue shortfall (ROIV) - MSN
Should Roivant’s One‑Off Driven Profitability Shift Require Action From Roivant Sciences (ROIV) Investors? - Sahm
[Form 4] Roivant Sciences Ltd. Insider Trading Activity - Stock Titan
Roivant anticipates $950M Moderna payment in July as it outlines 2H 2026 mosliciguat and IMVT-1402 readouts - MSN
ROIV Stock Price Prediction 2025-2026 | Roivant Sciences Ltd Forecast - 24/7 Wall St.
H.C. Wainwright reiterates Roivant Sciences stock rating on IMVT-1402 data By Investing.com - Investing.com South Africa
ROIV Maintained by Citigroup -- Price Target Raised to $42.00 - GuruFocus
Roivant Sciences Is Maintained at Buy by Citigroup - Moomoo
ROIV Reiterates by HC Wainwright & Co. -- Price Target Maintained at $34 - GuruFocus
Roivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy (NASDAQ:ROIV) - Seeking Alpha
Piper Sandler reiterates Roivant Sciences stock rating on trial progress By Investing.com - Investing.com Australia
Leerink raises Roivant Sciences stock price target on drug data By Investing.com - Investing.com South Africa
TD Cowen raises Roivant Sciences stock price target to $41 on trial data - Investing.com Australia
A Quick Look at Today's Ratings for Roivant Sciences(ROIV.US), With a Forecast Between $34 to $42 - Moomoo
Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2025 Earnings Call Transcript - Insider Monkey
Roivant Sciences Ltd. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ROIV) 2026-05-21 - Seeking Alpha
TD Cowen Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $41 - Moomoo
Roivant (ROIV) Climbs 15% on Swing to Profits - Insider Monkey
Roivant shares jump 10% on earnings beat despite revenue miss - Investing.com
Earnings call transcript: Roivant Sciences surprises with Q4 2026 EPS beat By Investing.com - Investing.com South Africa
Roivant Sciences Earnings Call Highlights High-Impact Pipeline - TipRanks
Roivant Sciences (ROIV) Q3 Loss Of US$265.9 Million Tests Long Term Bullish Narratives - simplywall.st
Earnings Call Summary | Roivant Sciences(ROIV.US) Q4 2025 Earnings Conference - 富途牛牛
Roivant Sciences Ltd. Stock 12‑Month Price Target Raised to $36.68, Implies 30% Upside - TradingView
Roivant/Immunovant Find Success In Tough-To-Treat RA, Where J&J Failed - Citeline News & Insights
Roivant Sciences (ROIV) Surges 15.2% on Strong Market Performanc - GuruFocus
Roivant Sciences stock hits all-time high of 30.35 USD By Investing.com - Investing.com Australia
Roivant Sciences Ltd (ROIV) Q4 2025 Earnings Call Highlights: Strategic Settlements and ... By GuruFocus - Investing.com Canada
Roivant Sciences (ROIV) Surges 14.8% to $32.38 - AlphaStreet
Roivant Sciences earnings beat by $0.57, revenue fell short of estimates - Investing.com India
Roivant reports Q4 FY2026 income on Moderna legal settlement - grafa.com
Why is Roivant Sciences stock surging today? By Investing.com - Investing.com South Africa
ROIV: High efficacy in refractory RA, strong cash, and major launches expected in the coming year - TradingView
2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug -- Barrons.com - Moomoo
Roivant Sciences Shares Jump 14.43% to $32.28 on Strong IMVT-1402 Rheumatoid Arthritis Data - International Business Times Australia
Roivant Sciences Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 - marketscreener.com
Earnings call transcript: Roivant Sciences Q4 2026 reveals strategic growth By Investing.com - Investing.com Australia
Sector Update: Healthcare - Moomoo
Roivant Sciences Q4 Earnings Call Highlights - Barchart.com
Immunovant Q4 Earnings Call Highlights - Yahoo Finance
Finanzdaten der Roivant Sciences Ltd-Aktie (ROIV)
Umsatz
Nettogewinn
Free Cashflow
ENV
Roivant Sciences Ltd-Aktie (ROIV) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Venker Eric | President & Immunovant CEO |
May 22 '26 |
Sale |
30.27 |
200,000 |
6,054,000 |
1,613,063 |
0.12%
0.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):